Yumanity Therapeutics, Inc. (NASDAQ:YMTX) Sees Large Growth in Short Interest

Yumanity Therapeutics, Inc. (NASDAQ:YMTXGet Rating) was the target of a large growth in short interest in May. As of May 15th, there was short interest totalling 138,000 shares, a growth of 25.5% from the April 30th total of 110,000 shares. Based on an average daily volume of 416,000 shares, the short-interest ratio is currently 0.3 days. Approximately 1.7% of the shares of the stock are short sold.

Shares of NASDAQ:YMTX opened at $1.06 on Wednesday. The firm has a fifty day moving average price of $1.31 and a two-hundred day moving average price of $2.08. The company has a market cap of $11.49 million, a price-to-earnings ratio of -0.25 and a beta of 0.88. Yumanity Therapeutics has a one year low of $0.95 and a one year high of $16.89.

Yumanity Therapeutics (NASDAQ:YMTXGet Rating) last posted its quarterly earnings data on Thursday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.00). The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $1.81 million. Yumanity Therapeutics had a negative return on equity of 162.54% and a negative net margin of 798.73%. As a group, sell-side analysts forecast that Yumanity Therapeutics will post -4.42 earnings per share for the current fiscal year.

Separately, Zacks Investment Research downgraded shares of Yumanity Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 14th.

Large investors have recently bought and sold shares of the stock. Morgan Stanley bought a new stake in Yumanity Therapeutics during the second quarter valued at $29,000. Jane Street Group LLC bought a new stake in Yumanity Therapeutics during the first quarter worth about $35,000. Virtu Financial LLC bought a new stake in Yumanity Therapeutics during the fourth quarter worth about $48,000. Bank of America Corp DE lifted its stake in Yumanity Therapeutics by 88,425.0% during the second quarter. Bank of America Corp DE now owns 7,082 shares of the company’s stock worth $83,000 after purchasing an additional 7,074 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in Yumanity Therapeutics during the third quarter worth about $106,000. 27.71% of the stock is owned by institutional investors.

About Yumanity Therapeutics (Get Rating)

Yumanity Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.

Featured Stories

Want More Great Investing Ideas?

Receive News & Ratings for Yumanity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yumanity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.